Grace Science

NGLY1 Deficiency is just the beginning. We have no intention of stopping there! A unique ecosystem of brilliant minds: Individuals who see the bigger picture and are willing to try a new model that allows for significant breakthroughs. Individuals who are collaborative & driven to learn and advance science. Matt Wilsey is a Silicon Valley entrepren... eur, angel investor, and start-up advisor. In addition to consumer products and services, Matt invests in and advocates for biomedical research, drug development, and genetic sequencing technologies. Carolyn Bertozzi is Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology (by courtesy) at Stanford University, and an Investigator of the Howard Hughes Medical Institute. George Sing is a venture capitalist and co-founder and CEO of life sciences and high technology startups. Led the VC seed investment in Regeneron Pharmaceuticals, Inc. and has been a board director since inception. Len Post has over thirty years experience in R&D at pharmaceutical and biotech companies. He is currently Chief Scientific Officer at Vivace Therapeutics. His previous position was Chief Scientific Officer of BioMarin Pharmaceutical, a company focused on rare genetic disease, where he was responsible for programs that included small molecules, proteins, and gene therapy. Becky Schweighardt is an innovative drug developer with broad development experience across multiple global drug approvals in rare disease. Her drug development experience reaches across all stages of development from discovery to post-marketing and across multiple drug modalities, including protein therapeutics, gene therapies, oligo nucleotides, and small molecules. She has over 20 years of academic and industry experience and spent the last 10 years developing therapeutics for rare disease at BioMarin Pharmaceutical. Brett Crawford is a glycobiologist with over 15 years of experience in biomarker and therapeutic discovery for rare genetic diseases. As a co-founder of Zacharon Pharmaceuticals, ...Read More